

Performance in Delivering Qtr 2 2018-19

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
31867	16/YH/0506	212039	COPD Exacerbation Study (SOPHOS)	Number Agreed	2	2	Date Agreed	08/06/2017	2	22/12/2017	2	Recruitment Finished	
31868	16/LO/1457	199790	AILD	Number Agreed	1	1	Date Agreed	17/10/2016	2	31/03/2018	2	Recruitment Finished	
31869	16/YH/0401	208313	A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid	Number Agreed	2	2	Date Agreed	02/02/2017	1	05/02/2018	1	Withdrawn By Sponsor	Sponsor Closed recruitment early. A second patient was identified and consented but screen failed.
31870	16/YH/0403	212896	FINCH 3	Number Agreed	1	1	Date Agreed	02/02/2017	0	19/03/2018	0	Withdrawn By Sponsor	Sponsor Closed recruitment early. Two patients were identified and consented but screen failed.
31871	16/EM/0439	199809	NOVELTY	Range Agreed	30	70	Date Agreed	14/04/2017	0	05/03/2018	0	Withdrawn By Sponsor	Sponsor closed recruitment early. Target was not reached as there were no patients who met the study criteria.
31872	16/HY/0402	208315	FINCH 2	Number Agreed	2	2	Date Agreed	25/03/2018	0	25/03/2018	0	Recruitment Finished	No patients fitting criteria
31873	16/EM/0133	184873	A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis	Number Agreed	3	3	Date Agreed	29/06/2018	1	18/05/2018	1	Withdrawn By Sponsor	Recruitment end date has been brought forward as UK target has been met. Too strict criteria
31874	16/WM/0395	210507	A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multicenter, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared	Number Agreed	2	2	Date Agreed	01/11/2019	2	07/06/2018	2	Withdrawn By Sponsor	Recruitment closed early
31875	16/EM/0384	182787	An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronar	Number Agreed	5	5	Date Agreed	31/05/2018	5	11/04/2018	5	Withdrawn By Sponsor	End date closed early by sponsor as study target has been reached
31876	16/LO/1811	214264	A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS	Number Agreed	2	2	Date Agreed	01/11/2019	0	14/05/2018	0	Withdrawn By Sponsor	Sponsor closed study early. Inclusion criteria was too strict (had 3 patients who screen-failed)
31878	17/LO/0825	223457	A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects with Active Sjogren's Syndrome	Number Agreed	1	3	Date Agreed	31/01/2018	1	07/09/2018	1	Recruitment Finished	